In a challenging market environment, DFLI, the stock for Chardan Nextech Acquisition 2, has reached a 52-week low, dipping to $2.49. According to InvestingPro analysis, the company's financial health ...
Chardan Capital Markets has recently initiated Mind Medicine (MindMed) Inc (MNMD) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on October 14, 2024, Leerink ...
Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target ...
Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $2.23 which represents a slight increase of $0.04 or 1.83% from the prior close of $2.19. The stock opened at $2.19 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback